Trial Profile

A phase 1/2a first-in-human study of the Alpha-synucleinopathies (ASYN) in Parkinson's Disease (PD) patients

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 06 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Jun 2021 According to an Amydis media release, the company received an award from the National Institute of Aging (NIA) at National Institutes of Health (NIH).The two-year Commercialization Readiness Pilot (CRP) Program award will provide additional funding toward the preparation and filing of an Investigational New Drug Application (IND) and completion of this FDA-reviewed adaptive study.
30 Apr 2021 New trial record
26 Apr 2021 According to an Amydis media release, the company has completed the pre-IND interaction with the USA Food and Drug Administration for the development plans of this drug. The pre-IND dossier included the design of this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com